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ABSTRACT 
 
The openness of the economy to the world market has many advantages but the lack of the protection 
of the domestic industry also imposes problems on the development of the domestic economy. In this 
sense, Kazakhstan, as part of the global market, is seeking its way in case of pharmaceutical 
industry. Currently the pharmaceutical sector is still in infancy stage of development to attempt the 
formation of an own independent pharmaceutical industry, the government has utilized several state 
programs and certain measures to stimulate the development of the pharmaceutical industry. The 
pharmaceutical market in Kazakhstan depends on foreign import drugs. In this article, we are 
considering the problems of Research and Development of original drugs in Kazakhstan. This paper 
explains the present barriers of the locally produced original drugs. The paper elaborates to eliminate 
public mismanagement, ineffective allocation of finance, to avoid loopholes in legislation (patent, fiscal, 
tax and preferences), to improve a cluster collaboration platform and economic barriers, 
commercialization technologies and not sufficient qualification of personnel and marketing and others. 
The theoretical and practical methods as well as administrative instruments of public services show 
the necessity of the adaptation of new approaches. This measure should be based on well-known 
overseas practices and legislative features that need to be applied accurately taking into account the 
specifications of Kazakhstan (legislation system, automation and digitalization process, big data, 
market circumstances and globalization impact and others). The paper is based on quantitative and 
qualitative data from scientific sources and legislation, official statistics, documents.  
Keywords: R&D, innovation, pharmaceutical industry, foreign investors, 
commercialization 
 
LITERATURE REVIEW 
 
Private and public sources also coexist in pharmaceutical R&D. The division of 
labour in pharmaceutical R&D between the two sectors is related, at least in principle, 
to the nature of the knowledge that is fostered (WHO, 2001). In most cases, the 
discovery of important new drugs is made by public institutions, which later license 
their development and exploitation to private firms. Some 70% of drugs with 
therapeutic gain were produced with government involvement (UNDP, 1999). 
Innovation in pharmaceuticals relies increasingly on the knowledge gleaned from 
preceding innovations and on generally available techniques (Merges and Nelson, 1994), 
(Long, 2000). 
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R&D involves discovery [preclinical studies] and development [clinical studies] of 
New Chemical Entities also known as New Molecular Entities. It is worth noting 
that of about 10,000 NCEs investigated to potentially treat a disease, only 250 might 
make it to animal testing and, of these, approximately 5–10 will qualify for testing in 
humans. Between 19 and 30% of Investigational New Drugs that begin Phase 1 trials 
make it to marketing (DiMasi, 2001). 
Successful technology commercialization (TC) is important for the survival in 
today’s competitive markets (Cooper, 2000). Mitchell and Singh (1996) view TC as ‘the 
process of acquiring ideas, augmenting them with complementary knowledge, 
developing and manufacturing saleable goods, and selling the goods in a market.’ 
This process begins with product conception; it includes the product definition, 
design, prototyping and pretesting stages; and it is consummated by effective product 
manufacturing and marketing. Successful TC allows the firm to satisfy its customers’ 
needs in terms of the cost, speed, quality, and newness attributes of their 
technologies. However, TC requires strong and varied capabilities, especially in 
manufacturing (Ettlie, 1997). Manufacturing capabilities are grounded in the firm’s 
people, skills, knowledge, processes, systems, and equipment. These capabilities can 
be assembled from different internal and external sources (Teece et al., 1997) and then 
deployed to create products and introduce them to the market in a timely manner. 
Private, public and even non-profit organizations also mobilize their idle, 
unexploited, and underutilized discoveries, inventions and innovations into the open 
market. Indeed, the commercialization of new knowledge – basic and applied 
research, technology breakthroughs, and scientific developments – is an ecosystem 
of research and technology commercialization, which is the focus of this themed 
section. This ecosystem is essentially a market that includes research joint ventures, 
strategic alliances, and licensing agreements involving universities, research parks and 
firms, as well as the formation of start-up companies that focus on science and 
technology. To put it differently, we are witnessing the emergence of new 
organizational forms and functions that promote research, knowledge and 
technology commercialization, such as technology transfer offices (within for-profit 
and non-profit organizations), science parks, incubators, and industry–university 
research centres (Markman et al., 2008). 
The first one is the rise in technology commercialization at research universities, 
which was stimulated by key legislation designed to promote the more rapid diffusion 
of technologies from universities to firms (e.g. the US Bayh-Dole Act of 1980 in the 
USA, and similar legislation in Europe, e.g. OECD, 2003), as well as an expansion of 
public-private partnerships by national governments (e.g. the US Commerce 
Department’s Advanced Technology Program and the UK Small Firms Merit Award 
for Research and Technology Program). A second trend is the rise of public–private 
research partnerships (e.g. science parks) and public investment in programs that 
support research and commercial interactions involving universities and firms. While 
these developments are more prominent in the USA, the rate of investment in such 
activities is actually higher outside the USA (Phan et al., 2005). 
Today's high drug prices are a direct consequence of a business model that uses a 
single payment to cover both the cost of manufacture of a drug and the cost of the 
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R&D carried out by manufacturers to discover it. A 20-year patent-based marketing 
monopoly is then granted to the drug's developers to prevent their prices from being 
undercut by ‘generic’ copies produced by manufacturers who do not have R&D costs 
to recover. Preventing such ‘free riding’ on R&D has become a global trade issue at 
the World Trade Organization (WTO) (Drahos and Braithwaite, 2002). 
Unfortunately, monopoly-based business models have unpleasant side effects. 
Since the primary responsibility of any company is to maximize return on investment, 
it is unsurprising that there is pressure on pharmaceutical companies to set drug 
prices to whatever level gives the highest return, excluding those individuals who 
cannot afford to pay, rather than maximizing the number of patients treated. There 
is also pressure to misuse the power given by patents, using them as anticompetitive 
weapons to block innovation and extend marketing monopolies. And there are 
growing fears that the huge growth in the use of patents is in itself starting to inhibit 
research (CIPR, 2003). 
Development of new drugs is a complex and costly process. It generally takes 10–
15 years, and studies have shown that it can cost between US$800 million to US$2 
billion to get a new drug to market, with similar, or even higher, costs for 
development of pharmaceuticals (DiMasi and Henry, 2007). 
There is little dispute about the importance to drug discovery of basic research at 
PSRIs under the traditional approach. Studies by Cockburn and Henderson showed the 
complex relationships between public and private research in the pharmaceutical 
industry (Cockburn and Henderson, 1997). Toole (2008) found a quantifiable correlation 
between investment in publicly funded basic research and corporately funded applied 
research: an increase of 1% in the funding of public basic research led to an increase 
of 1.8% in the number of successful applications for new molecular entities 
(compounds that have not been approved for marketing in the United States) after a 
lag of about 17 years. He found that a $1 investment in public-sector basic research 
yielded $0.43 in annual benefits in the development of new molecular entities in 
perpetuity (Toole, 2008). 
Pharmaceutical companies hold international patent rights which give them the 
exclusive right to produce a new drug for a specific period, which may run into 
decades after its development. It is only after the lapse of the patent that generic 
formulations are allowed into the market according to the current drug production 
laws (World Health Organization, 2016). 
 
MAIN CHARACTERISTICS OF THE PHARMACEUTICAL SECTOR 
OF KAZAKHSTAN 
 
The main economic circumstances in Kazakhstan 
The Kazakh relations with the usual data clearly show that the country is approaching 
the group of developed states, but its per capita GDP is still lagging behind the GDP 
of the OECD countries. According to the Gini indicator, income distribution is more 
evenly distributed than in OECD countries, and the expected life expectancy at birth 
is higher than expected on the basis of GDP. This is obviously related to the fact that 
relatively lower alcohol consumption and smoking are less widespread than even in 
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the more developed countries of the surrounding CIS region. Kazakhstan is the 9th 
biggest country in the World (Table 1). This is a great and special possibility for the 
Kazakh pharmaceutical industry. The low population density and the big territory 
would provide a niche for original drugs based on natural herbs collected from 
untouched «virgin» areas. 
 
Table 1 
 
Some indicators of Kazakhstan 
 
Name indicator 2001 2016 2017 
Population in thousand 14851 17918 18157 
Territory in square kilometre 2717300 2724900 2724900 
GDP, current USD billion 22.15 137.3 159.4 
GDP/capita current USD  1490 7714 8837 
Poverty rate (2,5 USD/day/capita) in 2010 year 0.7% 0.1 % 0.0% 
Poverty rate (5 USD/day/capita) in 2010 year 19.6% 8.8 % 5.1% 
Gini coefficient  0.366 0.278 0.287 
Life expectancy at birth (years) 65.76 72.41 72.95 
Source: The Ministry of National Economy of the Republic of Kazakhstan Committee on 
Statistics, 2018 
 
The transformation of the sector to market-based economy 
According to economists and politicians of Kazakhstan, the pharmaceutical industry 
is one of the most important pulling sectors of the Kazakh industry. They use phrases 
like «best prospect industry in Kazakhstan». Maybe this optimistic view is not just an 
overstatement, meanwhile the real story of the industry started only in 1996 when 
the DE monopolization happened. Eugene Brovko and Alexey Klochko clearly stated in 
their study: in «Kazakhstan pharmaceutical market started its formation in the middle 
1990s. In 1994, the State Joint Stock Holding «Pharmacia» owning 1832 pharmacies 
carried the provision of drugs in the country. After the DE monopolization of the 
Holding and privatization of its pharmacies, the national drug provision system was 
destroyed. In 1996, transformation processes allowed developing a drugs provision 
system based on market relationships» (Brovko and Klochko, 2017). 
In the light of the figures, an outside viewer would hardly understand why it is 
the best prospect industry in Kazakhstan. As shown in the figure below, this industry 
accounts for less than 1% of Kazakhstan’s industrial production and its contribution 
to exports is insignificant (Figure 1). 
However, it is true that the production of the industry is growing rapidly, with nearly 
three and a half times the domestic production. A near goal is that at least half of the 
domestic drug supply should be satisfied by domestic production. One of the most 
important issues for the future of the industry is whether or not this industry has the 
chance to develop original drugs any time in the future. The other or the traditional 
solution would be to keep importing the original medicines from abroad - most of 
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them mainly from the US and produce only the generic medicines in Kazakhstan's 
economy.  
 
Figure 1 
 
Production and investments into Kazakhstan’s pharmaceutical market 
 
 
Sources: The Ministry of National Economy of the Republic of Kazakhstan Committee on 
Statistics, 2018; Shinkeyeva, 2017 
 
Anyone who knows the Kazakh economy from inside of the country does not 
find it so weird that an industry below 1 % has such a distinct attention. The Kazakh 
economy is characterized by the predominance of the oil industry and its closely 
related sectors, the ratios are often a bit distorted. More than 50 % of the export 
comes from oil and gas export (Table 2). 
 
Table 2 
 
Macroeconomic Indicators, 2014–17 
 
Main indicators 2014 2015 2016 2017 
Nominal GDP (in billion KZT) 39 676 40 884 46 971 51 967 
Nominal GDP per capita (in USD) 12 807 10 511 7 714 8 837 
Real exchange rate change (KZT/USD) -10.8 -13.9 -26.7 10.4 
Merchandise exports, of which: 80.3 46.5 37.3 49.3 
Oil and gas exports 53.6 26.8 19.4 26.4 
Source: Sarsenov and Aldiyarov, 2018 
 
The Kazakh pharmaceutical industry, and also other sectors, was partly offset by 
the fact that oil and gas reserves made the Kazakh economy a raw material producing 
economy. The pharmaceutical industry was considered to be a high technology sector 
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in the former Soviet Union and was developed in the centre mainly in Russia and not 
in peripheral republics like Kazakhstan.  
The pharmaceutical industry is a specific market that is related to several spheres 
of economic and human activities. On the other hand, this industry plays a vital role 
in national security at the state level. This market is extremely changeable because of 
new technologies and interdependent on other sectors, for instance, chemical and 
agricultural. 
Kazakhstan has developed the infrastructure of creating a line of original drugs. 
A half of this period has been devoted to a research program, and per sue, it is still 
under process. In turn, the government of Kazakhstan takes necessary steps for the 
adaptation transformation and free trade dictates the further integration process. 
In this article we would like to show that the transformation of the pharmaceutical 
industry simultaneously opens up new opportunities and challenges. Kazakhstan has 
made a decision to pursue its independence from the world market turbulence: 
national security first. This measure should prevent any counterfeit drugs that can 
raise the issue of national security (causing death, disability and trauma). 
 
International agreements influencing the market 
While Kazakhstan is a member of the WTO, Kazakhstan is currently part of two 
economic co-operations that have a relatively close relationship with the most 
developed parts of the former Soviet republics. In 2010 Kazakhstan created a 
Customs Union with Russia and with Belarus. 
It is difficult to evaluate and compare data with the KZT as the dollar exchange 
rate is changing significantly (Table 2). The actual data may be misleading, but the 
tendencies are apparent. An interesting comparison has been made by, for example, 
the Schneider Advisory Company on pharmaceutical prices. The price of five 
medicines (fever suppressors, Cold/flu, cough, analgesics) converted to dollars in 
Kazakhstan is twice as much as in Russia with the same customs debt.  
The Customs Union also serves to protect the domestic industry. While 
previously the duty was duty-free, import duties around 5-12% as a result of entry 
into the CU, protect imported goods from outside the CU. As more than four-fifths 
of the generic formulations of the medicines are used, the acquisition and production 
of these drugs will indirectly be supported within the CU countries. 
On May 29, 2014 Kazakhstan and its Customs Union partners signed a treaty to 
create a common economic space known as the Eurasian Economic Union (EAEU). 
The EAEU is expected to further integrate their economies, and provide for the free 
movement of services, capital and labour within their common territory. The 
government of Kazakhstan has asserted that EAEU agreements comply with WTO 
standards. Kazakhstan’s government is optimistic that further integration within the 
EAEU will make Kazakhstan more attractive for foreign investment by expanding 
market access to those countries. Kazakhstan is a signatory of the Free Trade 
Agreement with CIS countries. In addition, as a member of the EAEU, Kazakhstan 
is party to the Free Trade Agreement between the EAEU and Vietnam (export.gov, 
2017).  
Regional and Business Studies Vol 10 No 1 
 45 
Local manufacturers produce basic pharmaceutical products that do not require 
innovative technologies. Market demand for specific complex pharmaceuticals is met 
entirely by imports. The largest share of imported pharmaceutics belongs to the U.S. 
18% followed by Germany and Russia with around 13% and 8.4% respectively. This 
is the reason why trade agreements have an important impact on medicines. Much 
of the generic pharmaceutical import still comes from Russia, while most of the 
original imports come from the USA and, to a lesser extent, EU Member States, such 
as Germany, Hungary or Poland. In the Kazakh pharmaceutical industry, one of the 
most important investors is the Polish «Polpharma». 
 
THE KEY ACTORS OF THE KAZAKH PHARMACEUTICAL 
INDUSTRY 
 
The local players 
Kazakhstan wants to achieve 50% self-sufficiency in pharmaceutical and health 
preservation products by 2018. In order to internationalize the industry, a major step 
in 2014 was the Good Manufacturing Practice (GMP) principles in the domestic 
pharmaceutical industry. In 2017, seven major companies in the pharmaceutical 
industry operated with these principles and they were certified due to this principle. 
In Kazakhstan, there are about 24 manufacturers of medicines that are focused 
on the production of generic drugs, which should provide an own Research and 
Development of original drugs on the territory of the republic. «Among the high 
production areas were the Almaty region 52.8% of total domestic production), the 
South Kazakhstan region 18.3% and Almaty 12.4%. 
In the regional context, the largest contribution to medications production is 
made by Almaty city and Almaty region – it accounted for more than 61.2% or 10.9 
thousand tons in 2016. The remaining 6.9 thousand tons were produced by 
enterprises of the South-Kazakhstan region (25.4%), Karaganda region 7.5% and 
other areas 5.9%. At the end of 2017, experts did not expect significant changes in 
the regional structure. 
At present the pharmaceutical industry in Kazakhstan is saturated with a variety 
of products, while the range of domestic products does not fully satisfy the domestic 
demand of consumers (The Ministry of National Economy of the Republic of Kazakhstan 
Committee on Statistics, 2018; Shinkeyeva, 2017). 
 
Foreign investors and their distribution by countries 
The main foreign pharmaceutical companies are attracted from developing countries, 
from Poland, Turkey, Russia and China, and it is time to attract developed countries 
like: USA, Canada, UK, France, Germany, Denmark, Switzerland and Japan for 
Research and Development of Kazakhstan’s original drugs (Table 3). 
Chempharm-SANTO Company being a part of the international pharmaceutical 
group Polpharma (Poland), is implementing the largest investment project in the 
South Kazakhstan region to modernise the existing pharmaceutical production of 
Chempharm in accordance with Good Manufacturing Practice international 
standards. The Polish investor invested $37 million in the plant (Uatkhanov, 2018).  
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Table 3  
 
Top Five Partners (Million, USD) 
 
Total Equity Securities Total Debt Securities 
All 
Countries 
64.908 100% 
All 
Countries 
9,196 100% 
All 
Countries 
55.713 100% 
United 
States 
34.403 53% 
United 
States 
4,859 52.8% 
United 
States 
29.544 53% 
Japan 4.375 6.7% 
United 
Kingdom 
860 9.4% Japan 3.601 6.4% 
France 3.749 5.7%. Japan 774 8.4% France 3.456 6.2% 
Germany 3.308 5.1% Switzerland 480 5.2% Germany 2.885 5.1% 
Canada 2.382 3.7% Netherlands 157 1.7% 
South 
Korea 
2.297 4.1% 
Source: export.gov, 2017b 
 
Pharmaceutical investment continues with state aid. Production in Hikma CIS 
Almaty will start in 2019 with a 6.5 billion KZT investment. Juldyz Kenan Co. LTD 
disposes of disposable medical plastic products for the manufacture of 1.7 billion 
KZT, Astana Pharmbiosyntesis invests in the manufacture of basic medicines 32.9 
billion KZT. Chempharm-Santo’s owner is the Polish Polpharma Group and their 
revenue in 2014 was about 55 million USD. The second biggest NOBEL Almaty 
Pharmaceutical Factory had only 22 million, meanwhile the other had less, between 
7-2 million USD only (export.gov, 2017c).  
 
The structure of the healthcare system of Kazakhstan 
The organogram below shows the structure of the health system. The organogram 
shows that the health care system is still centralized and largely state-funded.  
The non-commercial joint-stock company «Social Health Insurance Fund» was 
established in accordance with the Resolution of the Government of the Republic of 
Kazakhstan dated 01 July 2016 No. 389. 
The Fund is a non-profit organization in the organizational and legal form of a 
joint-stock company, the sole founder and shareholder of which is the Government 
of the Republic of Kazakhstan. 
For employers, the amount of deductions is stipulated as 1.5% of the employee's 
accrued income from 2018 to 2019, from January 1, 2020 - 2%. Individuals do not 
pay between 2018 and2020, since 2020 they will pay from two monthly wages. At the 
moment, payment and contributions for compulsory social health insurance for 
individuals from January 1, 2020 have been postponed. 
The state pays contributions for certain categories - in 2020 4% of the average 
monthly wage of the preceding two years of the current fiscal year, determined by 
the authorized body in the field of state statistics (paragraph 2 of Article 26 of the 
Law On Mandatory Medical Insurance) (Figure 2). 
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Figure 2  
 
The structure of the healthcare system of Kazakhstan  
 
 
 
INNOVATION, R&D POSSIBILITIES  
 
The underutilised R&D network, the fragmented institutional infrastructure  
Kazakhstan has enough scientific and technical potential, but the implementation of 
R&D results are very weak. There are research institutes in Kazakhstan and 
universities are not connected to industry, they focus their basic research on what 
industry can hardly benefit from and as a result of this, in Kazakhstan those patents 
are very rare from which the industry could develop brands. Basically Kazakhstan 
had some research institutes but they were not connected to the industry and their 
performances were not evaluated according to the practical implementation of their 
research or the financial success of their activity. High-tech product industrial 
innovations came from the Soviet system and Kazakhstan used to be on the 
periphery of the Soviet system.  
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In Kazakhstan, there is a decline in the clinical trials market. So, in 2015, only 12 
clinical trials were conducted, which is 3 times lower than in 2014. All clinical trials 
were conducted only by domestic manufacturers. The decrease is due to the obsolete 
regulatory framework, as the Rules for the conduct of clinical trials and (or) trials of 
pharmacological and medicinal products, medical devices and medical equipment 
were approved in November 2009. The main barriers for attracting international 
clinical research to Kazakhstan include: insufficient experience of the country's 
participation in clinical research; the absence of a register of clinical studies 
conducted in Kazakhstan; insufficient number of medical institutions for conducting 
clinical trials, since clinical research is carried out mainly by universities and research 
institutes; insufficient number of experienced researchers. Insufficient number of 
research institutions reduces the country's attractiveness for conducting clinical trials. 
Terms for the approval of clinical trials, which are 120-160 days, are a barrier to the 
participation of Kazakh medical institutions in international clinical trials. In addition, 
there is no regulatory procedure in Kazakhstan that regulates the importation of 
equipment and medical devices for clinical trials. 
Conducting international clinical research affects the development of medical 
science in terms of improving the level of skills of medical personnel, transfer of 
advanced technology. The sponsor of the Clinical Research provides equipment, 
which is then donated to the clinic for free. Thus, the conduct of clinical research 
can become a locomotive for the development of medicine. The main barriers to 
conducting clinical trials in the Republic of Kazakhstan are the incompatibility of 
medical organizations with the criteria for accreditation for conducting clinical trials, 
as well as the shortage of qualified specialists with GCP certificates. 
The consequences of the previous system still influence Kazakhstan’s R&D 
activity. Research institutes belonging to the public sector are mainly academic 
institutions and the research activity almost totally misses from the private sector. 
The government finances academic institutions, but there is no connection between 
their budget and the practical implementation of their research results. The scientists 
are evaluated according to their publication activity, if they want to be successful and 
get a better job, they have to publish in prestigious journals. If we evaluate our 
research institutes based on their publications, they are not among the best ones in 
the world. Personal career possibilities of the employees of research institutes 
contradict with the interest of the Kazakh economy.  
The patent developed by the researches belongs to the institute, their financial 
benefit is only marginal. Certainly, their prestige is based on the patents as well, but 
their position in the scientific community comes from their publication activity.  
All this makes it necessary to increase the efficiency and effectivity of the entire 
national research institution system and the system of commercialization of scientific 
R&D. 
Kazakhstan has several advantages in the field of developing and producing 
original drugs: 
- possesses unique flora and uses several Scientific-Research laboratories that 
enable to create original specimen on botanic base;  
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- big territory of the country gives possibilities for greenfield investments where 
the isolation of the investment site is important;  
- political stability and geographical location of Kazakhstan can have an advantage 
for a potential Centre for international companies; 
- custom free alliances of five countries created huge market opportunity 
(approximately 183,9 million people market) for the foreign investors; 
- in cooperation with international companies the establishment of joint ventures 
gives opportunities for accessing high technologies; 
- several government agencies are supporting the innovation activity with non-
refundable grants; 
- well educated, but not properly used labour force. 
Problems and barriers in front of the original drugs: 
- economic barriers; 
- commercialization activity is not developed; 
- insufficient qualification of personnel. 
Another problem in the domestic market is the lack of own innovative drugs. 
Kazakhstan is a country producing mainly generic drugs. The most of the domestic 
producers' products consist of low-cost medicines, which prevents the allocation of 
the required amount from the proceeds for R&D. 
 
Existing economic barriers  
Tax and duties policy should be changed in favour of R&D institutions, incumbent 
producers, investors and other stakeholders. Practically, the Government should 
adapt first minimal steps for creating a more competitive field: 
- by reducing corporate income tax for the amount of expenses which is used for 
purchasing new technics, transferring technologies, implementation of GMP 
Rule; 
- national producers consider the lack of tax agreements with some neighbours to 
be one of the barriers towards exports to those countries; 
- reducing the corporate income tax. 
 
Improper commercialization 
The government of Kazakhstan strives for setting a new blueprint concerning 
innovation and development of knowledge intensive industries. Despite scientific 
and practical background, the search for an efficient way of product 
commercialization has become more crucial and actual so far, indeed. 
The pharmaceutical market is divided almost equally into two major segments: 
State procurement and retail sales. State procurement of pharmaceuticals is 
implemented through tenders announced by regional and city health departments. A 
State-financed program funds state procurement of oncology and diabetic medicines. 
In 2009, the Ministry of Health set up SK-Pharmacy as a Single Distributor for 
supplying pharmaceuticals to State health institutions. The share of pharmaceuticals 
bought by the state through the Single Distributor system has increased and reached 
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85% by 2016. The remaining 15% of pharmaceuticals is directly purchased by 
hospitals and consists mainly of items used less frequently. In 2016 the Single 
Distributor bought pharmaceuticals worth approximately $300 million (Uatkhanov, 
2018). 
The weakest link in the creation of a national system of commercialization in 
Kazakhstan is the weak involvement of small and medium businesses in the process. 
In Kazakhstan, there are innovative developments that have effective results of the 
commercialization of innovative ideas. Experience shows that the introduction and 
commercialization of innovations is a complex process, and obtaining an economic 
effect involves several factors, including negative ones. Systemic approaches are 
needed for the formation of a national system for the commercialization of 
innovative scientific developments in order to support and protect domestic 
developers. 
One of the reasons is that Kazakhstan has a traditional approach to 
commercialization based on technology, where the role of the state is to help the 
inventor to develop a scheme for promoting the result of the scientific idea. In this 
case, the lack of entrepreneurial skills is compensated by a professional expert who 
is able to make an assessment of the idea, to determine its further commercial 
prospects, thereby eliminating risks. However, very progressive ideas with market 
potential do not often provide economic success, since marketing research is not 
conducted sufficiently and the managerial skills of the inventor are missing. 
 
Not Sufficient Qualification of Personnel 
One of the limiting factors in the development of the pharmaceutical industry is the 
high demand for qualified personnel. In the market there is an insufficient level of 
professional training and a shortage of qualified personnel. 
The discipline of clinical pharmacology is rapidly developing in the world 
pharmaceutical market. Clinical pharmacology studies various problems of drug 
therapy - the methodology of clinical trials, the metabolism of drugs, molecular 
pharmacogenetics, the analysis of drug intake, etc. The main direction of this 
discipline as a specialty is the study of questions concerning the health of patients. 
Specialists working in this field are trying to narrow the gap between drug 
manufacturers and clinicians. At present, there are about 200 clinical pharmacologists 
in Kazakhstan, of which only 5% are graduates, the rest have certificates. Moreover, 
there is no status of clinical pharmacologists, regulatory legal acts, quotas for training 
in the speciality of clinical pharmacology (The Ministry of HealthCare of the Republic of 
Kazakhstan, 2017). 
The number of employees increased from 16 578 thousand in 2003 to 22 985 
thousand in 2016 performing R&D. In fact, there is a problem of a shortage of 
personnel not only of skilled labour in the pharmaceutical, medical, agricultural and 
humanity fields in general. (The Ministry of National Economy of the Republic of Kazakhstan 
Committee on Statistics, 2018). 
Moreover, Table 4 illustrates that there is less investment in medical, agricultural, 
public, humanitarian domain than in technical and natural sciences, and the ratio 
went down in medical science from 6% in 2004 to 3% in 2016, meanwhile the 
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absolute number was increasing. The overall expenditures are 5 times higher. Also 
public science decreased from 4% in 2004 to 1% in 2016 (Table 4). 
 
Table 4 
 
Gross domestic expenditure on R&D by field of science 
 
Sector of sciences 2004 in million KZT % 2016 in million KZT % 
Technical 7317 52,78% 30193 45,34% 
Natural 3405 24,56% 23496 35,28% 
Agricultural  1302 9,39% 6885 10,34% 
Medical 889 6,41% 2278 3,42% 
Public 583 4,20% 1072 1,61% 
Humanities 367 2,65% 2676 4,02% 
Total 13863 100% 66600 100% 
Source: The Ministry of National Economy of the Republic of Kazakhstan Committee on 
Statistics, 2018 
 
As it might be assumed, if the aims are to play a crucial and leading role in this 
market, countries should pay to keep a high number of employment, like Germany -
114 thousand, France – 98,6 thousand, UK – 61,5 thousand, and Hungary – 23 
thousand, which had a high number of employment in 2015. 
 
THE STRATEGIC STEPS NECESSARY FOR R&D OF ORIGINAL 
DRUGS IN KAZAKHSTAN 
 
The development of the country's economy and the increase of the competitiveness 
of enterprises are impossible without the large-scale costs of economic entities for 
R&D. 
We consider each step separately here in details for Research and Development 
of original drugs in Kazakhstan: 
1) The analysis aimed at studying the market review, the volume and growth rates 
of the market, the ratio of the number of original and generic drugs and 
distribution of drugs; 
2) Marketing research aimed at studying the structure of the market, the consumers 
of products, studying the range and demand as well as a customer analysis, the 
segmentation of the market for consumers of the drugs studied, analysis of the 
internal and external competitive environment of the drugs, the determination of 
the optimal retail price of the new drugs;  
3) Identifying ways to advance the plan and budget to promote original drugs is the 
preparation of a plan for promotion and budgeting; 
4) Financing through the state budget or by attracting foreign investment for 
Research and Development of original drugs. Currently, the Ministry of 
Education and Science of the Republic of Kazakhstan jointly with the World 
Bank, is implementing a project to stimulate productive innovation. The joint 
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project of the Government of Kazakhstan and the World Bank is aimed at 
strengthening the capacity of key institutions of the national innovation system, 
it involves the introduction of market mechanisms for selecting and supporting 
innovative projects and technological start-ups, as well as encouraging the 
participation of the private sector in them. The aim of the Project is to stimulate 
high-quality, relevant research and the commercialization of technologies (The 
Ministry of Education and Science of the Republic of Kazakhstan, 2018). 
It is also possible to receive grants from National managing holding Baiterek, 
Centre of engineering and technology transfer, Enterprise Development Fund 
DAMU, Kazagromarketing, Centre for technology transfer and 
commercialization, KazagroInnovation can provide a significant amount of 
funding, accumulate a large amount of scientific and technical information and 
has a significant impact on the development trends of Kazakhstan's science; 
5) The share of domestic R&D expenditures from gross domestic product decreased 
from 0.25% in 2003 to 0.14% in 2016. The number of institutes and universities 
(enterprises) are 383 performing scientific Research and Development. 
Organization and conduct of Research and Development of original drugs should 
be made in accordance with the quality standards of good laboratory practice and 
good clinical practice. 
The GLP standard is a system of norms, rules and guidelines aimed at ensuring 
consistency and reliability of laboratory research results. The main task of GLP is 
to ensure the full traceability and recovery of the entire course of the research. 
This is of research of agricultural products, medical research, food additives and 
original drugs (Yestaev, 2018). 
GCP is the quality of clinical practice, covering the planning, implementation, 
completion and verification, analysis of results, reporting and documentation that 
ensures the scientific significance of research, their ethical acceptability and the 
full documentation of the clinical characteristics of the drugs studied. The 
influence of clinical pharmacology on the process of creating new drugs is mostly 
pronounced when conducting clinical research;  
6) The rights to an invention are protected by a patent, which is issued based on the 
results of an examination conducted in accordance with the Patent Law of the 
Republic of Kazakhstan. Expertise of applications for the grant of patents for 
inventions is carried out by an expert organization - National Institute of 
Intellectual Property of the Ministry of Justice of the Republic of Kazakhstan. 
The patent certifies the priority, authorship and exclusive right to an object of 
industrial property. A patent for an invention is valid for twenty years from the 
date of filing an application. Regarding an invention relating to a medicinal 
product, a pesticide (toxic chemicals) for use that requires permits in the manner 
prescribed by the legislation of the Republic of Kazakhstan on permits and 
notifications, the period of validity of the exclusive right and the patent certifying 
this right may be extended at the request of the patent holder, but not more than 
five years. (National Institute of Intellectual Property, 2017); 
7) The registration of the original drugs takes place at the National Centre for 
Expertise of medicines, in the case of medical devices and medical equipment it 
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is the role of the Ministry of Health of the Republic of Kazakhstan to determine 
the safety and quality of medicines. The safety and quality assessment are carried 
out to confirm the safety and quality of products, including those withdrawn from 
the market if they are in doubt concerning their quality, pharmacovigilance and 
monitoring results of side effects of medicines and prevention of the circulation 
of counterfeit products on the market of the Republic of Kazakhstan. Assessment 
of safety and quality is subject to drugs imported into the Republic of Kazakhstan 
and medicines and medical products produced in the territory of the Republic of 
Kazakhstan (National Center for Expertise of Medicines, 2018). 
8) Here I propose to consider the commercialization of technologies, since today 
there is the National Agency for Technological Development of the Baiterek 
Holding, which provides the commercialization of technologies for introducing 
(using) the results of scientific and (or) scientific and technical activities in their 
own production aimed at obtaining a positive economic effect. The financing 
condition is 50% of the applicant's own funds /50% of the grant, but not more 
than 200 million KZT. Starting from 2012, it is possible to receive innovative 
grants through the National Agency for Technological Development for three 
types of grants: 1) Commercialization of technologies; 2) Technological 
development of enterprises; 3) Technological development of the industry 
(National Agency for Technological Development of the Republic of Kazakhstan, 2018). 
Moreover, in the framework of the Law of the Republic of Kazakhstan On 
State Support of Industrial Innovation Activities», tax and budget incentives for 
innovation infrastructure and enterprises aimed at producing high-tech products 
are envisaged; 
9) Introduction of original drugs into production. In case of interest by 
pharmaceutical companies and obtaining mutually beneficial terms, the 
pharmaceutical company should be associated with Institutes and Universities 
and provide the responsibility of each party in terms of implementing Research 
and Development of original drugs. The Institute will be obliged to conduct 
market analysis, marketing of domestic and foreign markets, assess the 
profitability of products in conjunction with independent experts and harmonize 
the budget with state organizations, and conduct the Research and Development 
of original drugs. The University makes an agreement with a pharmaceutical 
company to provide qualified personnel. The pharmaceutical company will be 
obliged to introduce the original drugs into production and promote the products. 
 
CONCLUSION 
 
It is an important issue for a rapidly growing, but mainly oil-based economy to decide 
whether to develop independent industries such as the pharmaceutical industry or 
not. Kazakhstan has some intellectual capital related to the chemical industry because 
of the predominance of the oil industry. The question is whether this could be a 
sufficient basis for creating a specialized high-tech industry such as the 
pharmaceutical industry. The creation of original medicines would require a solid 
institutional background for the research of biochemistry and an industrial culture 
Aliyeva: A few steps ahead the state of Kazakhstan’s pharmaceutical industry 
 54 
which satisfy the requirements of good manufacturing practice, and this is what 
largely lacking in Kazakhstan. The emergence and expansion of foreign 
pharmaceutical investors from US, UK, Poland and Canada, however, warns that the 
pharmaceutical market is open to both Russia and Asian countries and is easily 
accessible from Kazakhstan. Our research shows that the radical shift towards 
original drugs is more a desire than reality. However, the generic drugs market may 
have real reserves that the Kazakh pharmaceutical industry would have to resort to. 
For this, close cooperation between industry and state is essential. The industry 
should be prepared for innovations, but the government should create the favourable 
business conditions for such a development. The economic policy and regulation 
should break down the administrative barriers that hinder industry development and 
should provide better protection against imported generic drugs in the market. Over 
the next few years, the positive state discrimination of the domestic pharmaceutical 
industry is justified. Without positive discrimination, the newborn drug industry 
would not be able to strengthen and would disappear before it could turn out to be 
viable. 
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